Last reviewed 2026-04-22 · How we verify

Optimized background ARV

Optimized background ARV refers to a tailored combination of antiretroviral drugs selected based on individual patient resistance testing and treatment history to maximize viral suppression in HIV infection.

Optimized background ARV refers to a tailored combination of antiretroviral drugs selected based on individual patient resistance testing and treatment history to maximize viral suppression in HIV infection. Used for HIV-1 infection in treatment-experienced patients with documented resistance.

At a glance

Mechanism of action

Background ARV regimens are customized antiretroviral therapy combinations chosen after genotypic or phenotypic resistance testing to ensure the patient's HIV strain remains susceptible to the selected agents. Hoffmann-La Roche's optimized approach integrates resistance data with pharmacokinetic considerations and individual patient factors to improve treatment outcomes and reduce the risk of virological failure and resistance development.

Approved indications

• HIV-1 infection in treatment-experienced patients with documented resistance

Common side effects

• Gastrointestinal disturbances
• Hepatotoxicity
• Lipid abnormalities
• Mitochondrial toxicity

Key clinical trials

• Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (PHASE2, PHASE3)
• Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance (PHASE1, PHASE2)
• Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients (PHASE2)
• UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection (PHASE3)
• Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children (PHASE1, PHASE2)
• INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. (PHASE2)
• A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients (PHASE4)
• A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.